Rescue experiments confirm that PKLR knockdown reverses the proliferative and glycolytic enhancement induced by USP3 overexpression, establishing a complete “USP3 → PKLR → metabolic reprogramming → tumor progression” signaling axis and providing new prognostic biomarkers and therapeutic targets for GBC. This evidence concerns the gene PKLR and neoplasm.